Trial Profile

A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

01 Feb 2023 Status changed from active, no longer recruiting to completed.
03 Mar 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
03 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com